VISmodegib for ORbital and Periocular Basal Cell Carcinoma

Carcinoma, Basal Cell Clinical Trial

— VISORB  

Official title:

VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02436408
• Other study ID #: UMCC 2014.022
• Secondary ID: HUM00082579
• Status: Completed
• Phase: Phase 4
• Start date: July 15, 2015
• Est. completion date: September 2020

Study information

• Verified date: September 2021
• Source: University of Michigan Rogel Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Basal cell carcinoma (BCCA) is the most common human cancer, and frequently affects facial structures. While rarely fatal, facial BCCA can be disfiguring and expensive to treat.

Vismodegib is a small molecule inhibitor of SMO developed for the treatment of tumors in which the Hh signaling pathway appears to contribute to the development and maintenance of tumorigenesis. Vismodegib was recently approved by the Food and Drug Administration (FDA) for treatment of metastatic and locally advanced BCCA. Recent reports have suggested that vismodegib treatment for orbital BCCA may facilitate eye preservation even if surgery is eventually required

In order to assess the potential of vismodegib to improve the ophthalmic outcomes following treatment for orbital and/or periocular BCCA, this study will follow patients with globe-threatening orbital and lacrimal-threatening periocular BCCA who are being treated with vismodegib as standard of care.

Patients with tumors that do not respond to treatment with Vismodegib, and those who have a good response but poor tolerance of Vismodegib, will be offered surgical excision of the tumor. Patients with a good response and good tolerance of Vismodegib may continue the treatment as long as clinically indicated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: September 2020
• Est. primary completion date: September 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients over 18 years of age with locally advanced or recurrent orbital or periorbital basal cell carcinoma (BCCA), or a medial canthal BCCA that threatens the lacrimal drainage system.

• Clinical assessment score obtained at baseline.

• Medical Oncology screening performed at baseline.

• Adequate BCCA size and location.

• Adequate hematopoietic capacity, hepatic and renal function.

• Male patients must agree to use condoms during treatment and for 3 months after last dose.

• Male patients must agree to not donate sperm during treatment and for 3 months after last dose.

• Participant must agree not to donate blood during the study and for 7 months after last dose.

• Informed consent signed.

• If the patient consents to enroll, then blood will be drawn and stored for biomarker analysis.

Exclusion Criteria:

• Inability or unwillingness to swallow capsules.

• Inability or unwillingness to comply with study procedures.

• Pregnant, lactating, or breast feeding women.

• Women of childbearing potential.

• Uncontrolled medical illness.

• Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.

• Age under 18 years.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Basal Cell

Intervention

Drug:
• Vismodegib

Locations

Country	Name	City	State
United States	University of Michigan Hospital	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Michigan Rogel Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS).	The VAWS was developed for the purpose of this study. It is made up of standard ophthalmic exam points, as well as subjective assessment of tearing and overall patient satisfaction. The maximum score is 50 and a score of 21 or greater will be considered a good outcome.	Until end of study treatment (up to 15 months after start of study treatment); treatment duration ranged from 53 - 386 days.
Secondary	Number of Patients With Progressive Disease (PD)	Treatment response will be determined per Response Evaluation Criteria in Solid Tumors (RECIST) protocol, using clinical measurements and/or tumor imaging measurements (determined by treating physician).	Until end of study treatment (up to 15 months after start of study treatment); treatment duration ranged from 53 - 386 days.
Secondary	Number of Patients With a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) AND Good Tolerance of Vismodegib	Tolerance will be self-reported by patient. Treatment response will be determined per Response Evaluation Criteria in Solid Tumors (RECIST) protocol, using clinical measurements and/or tumor imaging measurements (determined by treating physician).	Until end of study treatment (up to 15 months after start of study treatment); treatment duration ranged from 53 - 386 days.
Secondary	Number of Patients With a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) AND Poor Tolerance of Vismodegib	Tolerance will be self-reported by patient. Treatment response will be determined per Response Evaluation Criteria in Solid Tumors (RECIST) protocol, using clinical measurements and/or tumor imaging measurements (determined by treating physician).	Until end of study treatment (up to 15 months after start of study treatment); treatment duration ranged from 53 - 386 days.